| scholarly article | Q13442814 |
| P2093 | author name string | C Sohn | |
| I J Diel | |||
| G Bastert | |||
| E F Solomayer | |||
| F Schuetz | |||
| C Gollan | |||
| A Jaschke | |||
| P2860 | cites work | Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] | Q28195767 |
| Metastasis to bone: causes, consequences and therapeutic opportunities | Q29614310 | ||
| Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma | Q33970512 | ||
| The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma | Q34340400 | ||
| Preclinical models of bone metastases | Q34360931 | ||
| Bisphosphonates in the prevention of bone metastases: current evidence | Q34361007 | ||
| The clinical course of bone metastases from breast cancer | Q36027636 | ||
| Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival | Q36670757 | ||
| Bisphosphonates induce breast cancer cell death in vitro | Q40840471 | ||
| Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial | Q43514162 | ||
| Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer | Q44083704 | ||
| Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients | Q45151602 | ||
| Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. | Q51557042 | ||
| Intra-mammary tumor location does not influence prognosis but influences the prevalence of axillary lymph-node metastases. | Q52950362 | ||
| Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases | Q63966512 | ||
| Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis | Q67558785 | ||
| Clodronate decreases the frequency of skeletal metastases in women with breast cancer | Q71899912 | ||
| Reduction in new metastases in breast cancer with adjuvant clodronate treatment | Q74837359 | ||
| P433 | issue | 12 | |
| P921 | main subject | breast cancer | Q128581 |
| patient | Q181600 | ||
| bone marrow | Q546523 | ||
| P304 | page(s) | 2007-2011 | |
| P577 | publication date | 2008-07-29 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up | |
| P478 | volume | 19 |
| Q35870578 | A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma |
| Q36491378 | A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. |
| Q34138399 | ASCO 2009: What's New in Breast Cancer Therapy? |
| Q51741445 | Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer. |
| Q36491357 | Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there? |
| Q38007855 | Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated? |
| Q30982699 | Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials |
| Q26781435 | Adjuvant bisphosphonates in patients with breast cancer: does the potency matter? |
| Q42603658 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. |
| Q36216730 | Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes |
| Q38230839 | Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial |
| Q37845836 | Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. |
| Q37847341 | Anticancer evidence for zoledronic acid across the cancer continuum. |
| Q37812731 | Antitumor Effects and Anticancer Applications of Bisphosphonates |
| Q34348233 | Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay |
| Q46620695 | BONUS 5: 5th Annual Bone and The Oncologist New Updates |
| Q37418042 | Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? |
| Q38147841 | Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates |
| Q85183752 | Bisphosphonate Risks and Benefits: Finding a Balance |
| Q24203656 | Bisphosphonates and other bone agents for breast cancer |
| Q47693752 | Bisphosphonates and other bone agents for breast cancer. |
| Q37797755 | Bisphosphonates as Anticancer Therapy for Early Breast Cancer |
| Q26795493 | Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence |
| Q42874080 | Bisphosphonates in adjuvant therapy of breast cancer |
| Q21132670 | Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis |
| Q36963360 | Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate! |
| Q35750472 | Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline |
| Q39157481 | Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer |
| Q28081996 | Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma |
| Q53805388 | Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread. |
| Q46277856 | Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells |
| Q43712545 | Bone mineral density is a prognostic factor for postmenopausal caucasian women with breast cancer |
| Q37337487 | Bone targeted treatments in cancer - The story so far |
| Q64980540 | Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer. |
| Q28081294 | Bone-Targeted Therapy |
| Q34209663 | Breast Cancer 2012 - New Aspects |
| Q34939979 | Breast cancer at bone metastatic sites: recent discoveries and treatment targets. |
| Q35750453 | Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy? |
| Q26774808 | Circulating tumor cells in breast cancer |
| Q44635510 | Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. |
| Q37965768 | Denosumab and the current status of bone-modifying drugs in breast cancer |
| Q36925557 | Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake? |
| Q39022352 | Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer |
| Q64903290 | Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy. |
| Q36491529 | Does estrogen play a role in response to adjuvant bone-targeted therapies? |
| Q38173736 | Dormancy in breast cancer |
| Q36491459 | Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort |
| Q48185674 | Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up. |
| Q58795240 | Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer |
| Q34023727 | Future directions of bone-targeted therapy for metastatic breast cancer |
| Q92607493 | Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany |
| Q36283738 | Importance of antiresorptive therapies for patients with bone metastases from solid tumors |
| Q33587199 | Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial |
| Q35653826 | Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game |
| Q37742180 | Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG |
| Q53376377 | Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. |
| Q36668047 | Mitochondrial permeability transition pore as a selective target for anti-cancer therapy |
| Q34617936 | NCCN Task Force Report: Bone Health in Cancer Care |
| Q37917774 | New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response |
| Q37355487 | Optimal management of bone metastases in breast cancer patients |
| Q35583788 | Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. |
| Q34049239 | Oral bisphosphonate use and breast cancer incidence in postmenopausal women |
| Q33447971 | Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases |
| Q55030407 | Practical consensus recommendaton for adjuvant bone-modifying agents in breast cancer. |
| Q35750652 | Prevention and Treatment of Bone Metastases in Breast Cancer |
| Q35667318 | Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives |
| Q34613485 | Prevention of bone metastases and management of bone health in early breast cancer. |
| Q34967135 | Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells |
| Q37094622 | Prognostic factors for patients with bone-only metastasis in breast cancer |
| Q37483543 | Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases |
| Q34127953 | Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. |
| Q34042715 | Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years? |
| Q34115304 | Targeting mitochondria for cancer therapy |
| Q37777488 | The Evolving Role of Bone-Conserving Therapy in Patients With Breast Cancer |
| Q36187063 | The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany |
| Q44503403 | The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse |
| Q37808268 | The crossover of bisphosphonates to cancer therapy |
| Q37690073 | The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy |
| Q37944154 | The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer |
| Q34145863 | The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives |
| Q37800183 | The use of bisphosphonates in cancer treatment |
| Q54577990 | Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. |
| Q35667196 | Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice |
| Q34896573 | Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene |
| Q37401841 | Treatment options for breast cancer and bone metastases |
| Q46904792 | Turning ecology and evolution against cancer |
| Q37807047 | Understanding and Optimizing Bone Health in Breast Cancer |
| Q30318610 | Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant Radiotherapy |
| Q34122791 | Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma |
| Q58694739 | Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial |
| Q37960410 | Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? |
| Q37909355 | Zoledronic acid: multiplicity of use across the cancer continuum |
Search more.